
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Rockville, Md. - For the second consecutive year, dermatologists and their young atopic dermatitis patients celebrated a nonsteroidal holiday.